Personen

TOP 5 Publikationen:

1. Gründer G, Mertens L, Jungaberle A, Jungaberle H, Spangemacher M. Compassionate use of psilocybin for treatment-resistant depression in Germany.Lancet Psychiatry. 2026 13(2):91-93. Epub 2025 Sep 18.
2. Gründer G, Brand M, Mertens L, Jungaberle H, Kärtner L, Scharf DJ, Spangemacher M, Wolff M. Treatment with psychedelics is psychotherapy: beyond reductionism.Lancet Psychiatry. 2024 11(3):231-236. Epub 2023 Dec 12.
3. Mertens L, Koslowski M, Betzler F, Brand M, Evens R, Kärtner L, Jungaberle A, Jungaberle H, Majic T, Schmitz C, Ströhle A, Scharf D, Spangemacher M, Wolff M, Assadi Z, Bahri S, Becher L, Färber LV, Kirchen N, Kulakova E, Kunz L, Meijer A, Rohrmoser B, Wellek S, Berger M, Gründer G. Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial.JAMA Psychiatry. 2026 Mar 18. [Epub ahead of print].
4. Spangemacher M, Mertens L, Färber LV, Jungaberle A, Jungaberle H, Gründer G. Psilocybin as a Disease-Modifying Drug—a Salutogenic Approach in Psychiatry.Dtsch Arztebl Int. 2024 121(26):868-874. Epub 2024 Dec 27.
5. Gründer G, Mertens L, Spangemacher M, Meyer-Lindenberg A, Jungaberle H. Psychedelics: The pathway to implementation in the European healthcare systems.Eur Neuropsychopharmacol. 2025 102:41-48. Epub 2025 Dec 2.